Table S5 from Vγ9Vδ2 T Cells Express an Antitumor Profile Associated with Anti–PD-(L)1 Responses and Activation Defects Restored by Anti-BTN3A in Triple-Negative Breast Cancer

This is a Quantitative Study study.

Key Points

Vgamma9Vdelta2 T cells show an enhanced antitumor profile associated with PD-(L)1, impacting responses in triple-negative breast cancer.
Differentially expressed genes reveal significant variations between Vgamma9Vdelta2 T cells, Vdelta1 T cells, and abCD8 Tem in untreated breast tumors.
Analysis focuses on gene expression in Vgamma9Vdelta2 T cells versus Vdelta1 T cells and abCD8 Tem in primary tumors, highlighting therapeutic avenues.
Results indicate potential for restoring activation defects in Vgamma9Vdelta2 T cells using anti-BTN3A, warranting further investigation.

Analysis shows Vgamma9Vdelta2 T cells exhibit antitumor profiles in triple-negative breast cancer, suggesting roles of PD-(L)1 and anti-BTN3A.

Differentially expressed genes between Vg9Vd2 T cells versus Vd1 T cell and abCD8 Tem in untreated primary breast tumors, related to Figure 2

No takes yet. Share an insight, caveat, or question.

Fattori et al. (2025) studied this question.

View at Publisher

Ask AI

Bookmark

Share